Bio-Path Holdings Amends Charter for New Preferred Stock with 51% Voting Power, Appoints Scientific Advisors

summarizeSummary

Bio-Path Holdings completed its domestication to Wyoming and authorized a new Series S Preferred Stock class that holds 51% of the company's diluted voting power, signaling a major corporate control shift amidst severe financial distress. The company also appointed two new members to its Scientific Advisory Board, granting them substantial stock options.

check_boxKey Events

• Corporate Domestication Completed

  The company completed its domestication from Delaware to Wyoming on March 5, 2026.

• New Preferred Stock with 51% Voting Power Authorized

  A new class of Series S Preferred Stock was authorized, consisting of 51 shares, each convertible into one common share and holding 1% of the company's diluted voting power, effectively granting 51% of the total diluted voting power to this new class.

• Scientific Advisory Board Appointments

  Dr. Wendy M. Charles and Michael Hickey were appointed to the newly created Scientific Advisory Board, effective February 10, 2026, bringing expertise in clinical research and oncology.

• Advisory Board Compensation Includes Options

  Each new advisory board member was issued 100,000 stock options with a three-year expiration and a $0.06 exercise price, totaling 200,000 options.

auto_awesomeAnalysis

The most critical aspect of this filing is the amendment to the Articles of Incorporation, which includes the domestication to Wyoming and, more significantly, the creation of a new class of Series S Preferred Stock. This new class, with 51 authorized shares each carrying 1% of the diluted voting power, effectively grants 51% of the company's voting control to this preferred stock. For a company already facing severe financial distress, including zero cash, a going concern warning, and operational pauses, this move strongly suggests a fundamental restructuring of control, potentially paving the way for a new controlling investor or a significant recapitalization effort. While this could be a necessary step for survival, it represents a substantial shift in power away from existing common shareholders. Additionally, the company appointed two experienced professionals, Dr. Wendy M. Charles and Michael Hickey, to its Scientific Advisory Board, which is a positive step for its scientific direction. However, the compensation package for these advisors includes 200,000 stock options in total, representing a significant potential dilution relative to the company's current outstanding shares and small market capitalization.